Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 20, 2025
Lead Product(s) : LBL-024,Etoposide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Leads Biolabs Earns FDA Orphan Status for LBL-024 in Neuroendocrine Cancer
Details : LBL-024 is a tetravalent bispecific antibody that simultaneously targets PD-L1 and 4-1BB, serving dual functions. It is being evaluated for the treatment of neuroendocrine cancer.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 22, 2024
Lead Product(s) : LBL-024,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LBL-024,Cisplatin,Etoposide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Leads Biolabs' LBL-024 Receives Breakthrough Designation in China
Details : LBL-024 is a bispecific antibody, binds to PD-L1 with high affinity, blocking the PD-L1/PD-1 pathway while activating the 4-1BB pathway in the tumor microenvironment.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : LBL-024,Cisplatin,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LBL-034
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Leads Biolabs Receives Orphan Drug Designation for LBL-034 in Multiple Myeloma
Details : LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is being developed by Leads Biolabs for treatment of multiple myeloma (MM).
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 11, 2024
Lead Product(s) : LBL-034
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LBL-024
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CDE Approves Pivotal Study of LBL-024, an Anti-PD-L1/4-1BB Bispecific Antibody
Details : LBL-024 is a bispecific antibody targeting PD-L1 and 4-1BB, blocking immunosuppression while activating the costimulatory pathway in tumors.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : LBL-024
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LBL-024
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 06, 2023
Lead Product(s) : LBL-024
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LBL-034
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 22, 2023
Lead Product(s) : LBL-034
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LBL-007,Toripalimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Chime Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to accelerate LBL-007, a novel antibody targeting the LAG-3 pathway, development and manufacturing for speedy clinical advancement for solid tumors.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
June 30, 2023
Lead Product(s) : LBL-007,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Chime Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : LBL-033
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LBL-033 is a T-cell engager, bispecific antibody, targeting MUC16-expressing tumor cells and CD3-expressing T cells, which is investigated for treatment for advanced solid tumors including ovarian cancer.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 16, 2023
Lead Product(s) : LBL-033
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LBL-033
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
March 22, 2023
Lead Product(s) : LBL-033
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable